The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers identified gene expression patterns that predict patient response to multiple myeloma drugs. These "footprints" revealed a strategy for sequential therapy with daratumumab and selinexor, improving patient survival.
Area Of Science
- Oncology
- Genomics
- Pharmacology
Background
- Multiple myeloma (MM) is a cancer of plasma cells with several approved therapies.
- Identifying predictive biomarkers for drug response is crucial for optimizing MM treatment strategies.
Purpose Of The Study
- To perform an integrated functional genomic analysis of MM patient samples to discover predictive biomarkers for drug sensitivity.
- To investigate the mechanistic basis of drug response and resistance and to identify novel therapeutic strategies.
Main Methods
- Integrated analysis of ex vivo drug sensitivity, clinical variables, cytogenetics, mutational profiles, and transcriptomes from MM patient samples.
- Development of a multiple myeloma transcriptomic topology to identify predictive "footprints" for drug sensitivity.
- Validation of transcriptomic footprints for daratumumab (DARA) and selinexor (SELI) using clinical response data.
Main Results
- A multiple myeloma transcriptomic topology was established, revealing "footprints" associated with ex vivo drug sensitivity.
- Transcriptomic footprints accurately classified clinical responses to DARA and SELI.
- Anticorrelated resistance mechanisms for DARA and SELI were identified, suggesting a rationale for sequential therapy.
Conclusions
- Functional genomic analysis provides predictive biomarkers and mechanistic insights for multiple myeloma drug response.
- Sequential therapy with SELI following DARA-containing regimens is associated with improved survival, supporting an evolutionary-based treatment strategy.
- The developed computational framework can guide the identification of improved therapeutic strategies for multiple myeloma.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...